复方七芍降压片治疗高血压病伴胰岛素抵抗

Compound Qishao Antihypertensive Tablets Treatment of Hypertension With Insulin Resistance

目的探讨复方七芍降压片治疗高血压病伴胰岛素抵抗的临床疗效及机制。方法将80例高血压病患者随机分为治疗组(40例)和对照组(40例),治疗组予口服复方七芍降压片,对照组服用卡托普利,疗程均为6周,观察治疗前后2组空腹血糖(FPG)、空腹血清胰岛素(FINS)、胰岛素敏感指数(ISI)和血压、血液流变学的变化。结果治疗组FPG、FINS、血压、血液流变学均下降,ISI升高,治疗前后自身比较差异有显著性(P<0.05,P<0.01)。结论复方七芍降压片对高血压病伴胰岛素抵抗有较好的临床疗效且无明显毒副反应。

Objective To investigate the clinical efficacy and mechanism of the compound Qishao antihypertensive tablets （Sanqi,Baishao, Tianma, etc. ） in the treatment of hypertension with insulin resistance. Methods 80 patients meeting the inclusion criteria for hypertension were randomly divided into treatment group（ 40 cases ） and control group （ 40 cases）. The treatment group was treated with the compound Qishao antihypertensive tablets,and the control group was given captopril for 6 weeks. Their fasting plasma glucose （ FPG） , fasting serum insulin （ FINS ）, insulin sensitivity index （ ISI） and blood pressure,blood rheology changes were observed before and after treatment. Results The fasting plasma glucose （ FPG ）, fasting serum insulin （ FINS）, blood pressure, blood rheology decreased, insulin sensitivity index （ ISI ） increased in the treatment group, and there was statistically significant difference before and after treatment （ P 〈 0.05, P 〈 0.01 ）. Conclusion The compound Qishao antihypertensive tablets in hypertensive patients with insulin resistance have better clinical efficacy with no apparent toxicity.